January 10, 2020
German pharma giant Bayer and British biotech firm Exscientia have announced a three-year partnership focused on the use of Artificial Intelligence in cardiovascular and oncology drug discovery.
The collaboration will initially see the companies work on three early-stage research projects, combining Bayer’s data and drug discovery capabilities and Exscientia’s Centaur Chemist platform.
October 1, 2019
Novartis is teaming up with Microsoft on a new artificial intelligence initiative focused on drug discovery and development. The new efforts will primarily be focused in Novartis’ newly announced AI innovation lab.
As part of the deal Novartis will be employing Microsoft’s AI tools to help its scientist with computational hurdles in life sciences including generative chemistry, image...
May 2, 2018
In a recent medium.com blog post, Daphne Koller — an artificial intelligence researcher at the Department of Computer Science at Stanford University and, until just a few months ago, chief computing officer at Alphabet’s Calico Labs — announced her up-and-coming foray into machine learning-powered drug discovery.
Called insitro (a portmanteau of “in silico” and “in vitro”), the new endeavor looks...
April 20, 2018
BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States. Existing backer Woodford Investment Management also participated in the round, which brings the company’s total funds raised to over $200 million.
“We are very pleased with the response to the fundraising," Ken Mulvany,...